Who are Bovizole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Arava, Hexalen, Prilosec, Inderal, Oxsoralen-Ultra, Omeprazol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thiabendazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Bovizole — Competitive Intelligence Brief

Bovizole (THIABENDAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic. Area: Infectious Disease.

marketed Anthelmintic Cytochrome P450 1A2 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Bovizole (THIABENDAZOLE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bovizole TARGET	THIABENDAZOLE		marketed	Anthelmintic	Cytochrome P450 1A2	1967-01-01
Arava	LEFLUNOMIDE	Sanofi	marketed	Antirheumatic Agent [EPC]	Cytochrome P450 1A2	1998-01-01
Hexalen	ALTRETAMINE	Eisai	marketed	Alkylating Drug	Cytochrome P450 1A2	1990-01-01
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	marketed	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Oxsoralen-Ultra	METHOXSALEN	Bausch Health	marketed	Photoactivated Radical Generator [EPC]	Cytochrome P450 1A2	1954-01-01
Omeprazol	Omeprazol	RenJi Hospital	marketed		ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-12-08 — Prilosec · 10835488 · Formulation · US
2036-12-08 — Prilosec · 10076494 · Formulation · US

Sponsor landscape (Anthelmintic class)

· 2 drugs in this class
Swiss Tropical & Public Health Institute · 2 drugs in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bovizole — Competitive Intelligence Brief. https://druglandscape.com/ci/thiabendazole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab